-Advertisement-
-Advertisement-
Oncology
Study identifies optimal treatment options for advanced hepatocellular carcinoma
A comprehensive study involving 23 randomized controlled trials has shed light on optimal treatment options for advanced hepatocellular carcinoma (HCC). In the first-line treatment, the combination of a PD-1 inhibitor with bevacizumab and the combination of PD-1 inhibitors with TKIs or bevacizumab demonstrated significant efficacy in extending overall survival and...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Contact
© 2024 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved